After exercise cells from the bladder are shed naturally in your urine and the DNA contained in these cells is collected for analysis.
The BCA-1 Test uses an ‘oligonucleotide array’ to analyse the DNA. It shows up genetic alterations (genetic markers) using a colour coding system.
The results are based on the level of genomic alterations observed across all chromosomes as identified by ArrayGenomics’ clinical research to validate the BCA-1 Test. They correlate chromosomal activity with the probability of non muscle-invasive bladder cancer as defined in the World Health Organisation (WHO) guidelines.
The BCA-1 Test has been shown in clinical trials to detect the presence of bladder cancer with overall sensitivity of 95%.
The BCA-1 Test also looks in particular at 27 genomic sequences - or markers - which are known to be involved in bladder cancer. These may be useful for your doctor to help plan your treatment.
The BCA-1 Test is the only bladder cancer test to analyse 27 genomic markers covering all known bladder cancers.
The comments will consider other information if you have chosen to share this, such as your medical history and risk factors.